Miralax and Haematocrit abnormal - a phase IV clinical study of FDA data

Summary:

Haematocrit abnormal is reported as a side effect among people who take Miralax (polyethylene glycol 3350), especially for people who are female, 60+ old, also take Zofran, and have Non-small cell lung cancer metastatic.

The phase IV clinical study analyzes which people have Haematocrit abnormal when taking Miralax. It is created by eHealthMe based on reports of 80,819 people who have side effects when taking Miralax from the FDA, and is updated regularly.

What is Miralax?

Miralax has active ingredients of polyethylene glycol 3350. It is often used in constipation. eHealthMe is studying from 81,754 Miralax users. Check the latest studies of Miralax.

What is Haematocrit abnormal?

Haematocrit abnormal is found to be associated with 283 drugs and 595 conditions by eHealthMe. Check the latest studies of Haematocrit abnormal.

On Jul, 14, 2026

80,819 people reported to have side effects when taking Miralax.
Among them, 15 people (0.02%) have Haematocrit abnormal.

Could Miralax cause Haematocrit abnormal?

Among these 15 people:

What is the gender of people who have Haematocrit abnormal when taking Miralax? *

female: 78.57 %
male: 21.43 %

What is the age of people who have Haematocrit abnormal when taking Miralax? *

What are other drugs people take besides Miralax? *

What are other side effects people have besides Haematocrit abnormal? *

Haemoglobin Abnormal: 9 people, 60.00%
Thrombocytopenia (decrease of platelets in blood): 7 people, 46.67%
Nausea And Vomiting: 6 people, 40.00%
Blood Alkaline Phosphatase Abnormal: 4 people, 26.67%
Blood Bilirubin Abnormal: 4 people, 26.67%
Fever: 3 people, 20.00%
Blood Urea Abnormal: 3 people, 20.00%
Blood Sodium Abnormal: 3 people, 20.00%
Blood Potassium Abnormal: 3 people, 20.00%
Blood Phosphorus Abnormal: 3 people, 20.00%

What are the existing conditions these people have? *

Non-Small Cell Lung Cancer Metastatic (type of epithelial lung cancer spreads to other parts): 3 people, 20.00%
Ovarian Cancer (cancer of ovary): 2 people, 13.33%
Prostate Cancer: 1 person, 6.67%
Mitral Valve Disease (disease of mitral valve of heart): 1 person, 6.67%
High Blood Cholesterol: 1 person, 6.67%
Bipolar Disorder (mood disorder): 1 person, 6.67%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Miralax and have Haematocrit abnormal?

- Check whether Haematocrit abnormal is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Miralax:

Miralax (81,754 reports)

Browse all side effects of Miralax:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Haematocrit abnormal:

Haematocrit abnormal (283 drugs)

Browse all the conditions that are associated with Haematocrit abnormal:

Haematocrit abnormal (595 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on polyethylene glycol 3350 (the active ingredients of Miralax) and Miralax (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.